DK2925889T3 - Diagnostiske markører til behandling af celleproliferationsforstyrrelser med telomeraseinhibitorer - Google Patents

Diagnostiske markører til behandling af celleproliferationsforstyrrelser med telomeraseinhibitorer Download PDF

Info

Publication number
DK2925889T3
DK2925889T3 DK13858528.6T DK13858528T DK2925889T3 DK 2925889 T3 DK2925889 T3 DK 2925889T3 DK 13858528 T DK13858528 T DK 13858528T DK 2925889 T3 DK2925889 T3 DK 2925889T3
Authority
DK
Denmark
Prior art keywords
treatment
cell proliferation
diagnostic markers
proliferation disorders
telomerase inhibitors
Prior art date
Application number
DK13858528.6T
Other languages
English (en)
Inventor
Bart Burington
Hui Wang
Kevin Eng
Ekaterina Bassett
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/802,035 external-priority patent/US9200327B2/en
Application filed by Geron Corp filed Critical Geron Corp
Application granted granted Critical
Publication of DK2925889T3 publication Critical patent/DK2925889T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G01N2333/9128—RNA-directed DNA polymerases, e.g. RT (2.7.7.49)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
DK13858528.6T 2012-11-30 2013-11-27 Diagnostiske markører til behandling af celleproliferationsforstyrrelser med telomeraseinhibitorer DK2925889T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261732263P 2012-11-30 2012-11-30
US201361780851P 2013-03-13 2013-03-13
US13/802,035 US9200327B2 (en) 2012-11-30 2013-03-13 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US201361798478P 2013-03-15 2013-03-15
US201361809228P 2013-04-05 2013-04-05
PCT/US2013/072302 WO2014085632A1 (en) 2012-11-30 2013-11-27 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Publications (1)

Publication Number Publication Date
DK2925889T3 true DK2925889T3 (da) 2019-01-02

Family

ID=50828470

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13858528.6T DK2925889T3 (da) 2012-11-30 2013-11-27 Diagnostiske markører til behandling af celleproliferationsforstyrrelser med telomeraseinhibitorer
DK18192236.0T DK3495495T3 (da) 2012-11-30 2013-11-27 Diagnostiske markører til behandling af celleproliferative forstyrrelser med telomeraseinhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18192236.0T DK3495495T3 (da) 2012-11-30 2013-11-27 Diagnostiske markører til behandling af celleproliferative forstyrrelser med telomeraseinhibitorer

Country Status (24)

Country Link
EP (3) EP3495495B1 (da)
JP (2) JP6359028B2 (da)
KR (3) KR102174763B1 (da)
CN (2) CN111494629A (da)
AU (3) AU2013352105B2 (da)
BR (1) BR112015012507B1 (da)
CA (1) CA2892445C (da)
CY (1) CY1124140T1 (da)
DK (2) DK2925889T3 (da)
ES (3) ES2865446T3 (da)
HK (1) HK1215874A1 (da)
HR (2) HRP20181991T1 (da)
HU (1) HUE054053T2 (da)
IL (3) IL282112B (da)
LT (2) LT3495495T (da)
MX (1) MX362094B (da)
NZ (2) NZ708654A (da)
PL (2) PL3495495T3 (da)
PT (2) PT3495495T (da)
RS (1) RS61513B1 (da)
SG (1) SG11201504209YA (da)
SI (2) SI3495495T1 (da)
WO (1) WO2014085632A1 (da)
ZA (2) ZA201900759B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3029154B1 (en) 2008-10-17 2017-10-04 Geron Corporation Method for identification of sensitivity of a patient to telomerase inhibition therapy
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
JPWO2018207952A1 (ja) * 2017-05-12 2020-04-16 国立大学法人九州大学 発毛及び／又は育毛用組成物
KR20210038895A (ko) * 2018-07-31 2021-04-08 제론 코포레이션 텔로머라제 억제제에 의한 치료로부터 이익일 것 같은 환자를 확인하는 방법
GB201818792D0 (en) * 2018-11-19 2019-01-02 Telonostix Ltd Compounds for telomere length-related treatment of cancer
EP3674418A1 (en) * 2018-12-26 2020-07-01 Life Length S.L. Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
CN114306602B (zh) * 2020-09-28 2024-06-11 中国科学院上海营养与健康研究所 靶向tert在调节皮肤及毛发色素中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
CA2274586A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
JPH11276182A (ja) * 1997-12-26 1999-10-12 Chugai Pharmaceut Co Ltd 逆転写酵素モチーフを有する新規遺伝子
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7695904B2 (en) 2002-01-31 2010-04-13 University Of Utah Research Foundation Reducing non-target nucleic acid dependent amplifications: amplifying repetitive nucleic acid sequences
US20040234961A1 (en) * 2002-04-22 2004-11-25 Fordyce Colleen A. Telomere length determination and applications
EP1585974B1 (en) 2003-01-24 2013-02-27 University of Utah Methods of predicting mortality risk by determining telomere length
AU2004271215B2 (en) 2003-09-09 2009-07-16 Geron Corporation Modified oligonucleotides for telomerase inhibition
US7485717B2 (en) 2004-07-02 2009-02-03 Geron Corporation Synthesis of protected 3′-amino nucleoside monomers
CN104997783A (zh) * 2005-03-25 2015-10-28 Alt解决方案公司 端粒酶阳性细胞中端粒长度的调节和癌症治疗
WO2006113470A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
EP3029154B1 (en) * 2008-10-17 2017-10-04 Geron Corporation Method for identification of sensitivity of a patient to telomerase inhibition therapy
US9689028B2 (en) 2008-12-22 2017-06-27 University Of Utah Foundation Monochrome multiplex quantitative PCR
US20110207128A1 (en) 2010-02-16 2011-08-25 Cawthon Richard M Methods and kits for determining biological age and longevity based on gene expression profiles
WO2012135125A1 (en) * 2011-03-28 2012-10-04 Geron Corporation Telomere length measurement in formalin-fixed, paraffin embedded (ffpe) samples by quantitative pcr

Also Published As

Publication number Publication date
CN104937110A (zh) 2015-09-23
ES2865446T3 (es) 2021-10-15
HUE054053T2 (hu) 2021-08-30
JP6359028B2 (ja) 2018-07-18
EP3495495B1 (en) 2020-12-23
PT2925889T (pt) 2018-12-12
DK3495495T3 (da) 2021-03-22
BR112015012507A2 (pt) 2017-07-11
LT3495495T (lt) 2021-02-25
EP3882355C0 (en) 2023-12-20
KR102348240B1 (ko) 2022-01-10
CA2892445A1 (en) 2014-06-05
PL2925889T3 (pl) 2019-02-28
EP3882355B1 (en) 2023-12-20
WO2014085632A1 (en) 2014-06-05
AU2022202808A1 (en) 2022-05-19
CA2892445C (en) 2022-06-28
BR112015012507A8 (pt) 2019-10-08
SI3495495T1 (sl) 2021-07-30
KR20210112394A (ko) 2021-09-14
CN111494629A (zh) 2020-08-07
JP2016501523A (ja) 2016-01-21
ZA201900759B (en) 2020-10-28
SI2925889T1 (sl) 2019-01-31
KR102174763B1 (ko) 2020-11-06
EP2925889B1 (en) 2018-09-05
IL239035B (en) 2020-09-30
KR20150091491A (ko) 2015-08-11
SG11201504209YA (en) 2015-06-29
IL239035A0 (en) 2015-07-30
ES2972330T3 (es) 2024-06-12
IL282112A (en) 2021-05-31
NZ748624A (en) 2020-08-28
EP2925889A1 (en) 2015-10-07
IL282112B (en) 2022-09-01
BR112015012507B1 (pt) 2023-03-07
EP3495495A1 (en) 2019-06-12
ZA202101317B (en) 2023-03-29
EP3882355A1 (en) 2021-09-22
LT2925889T (lt) 2018-12-27
PT3495495T (pt) 2021-03-22
AU2019283840A1 (en) 2020-01-23
MX362094B (es) 2019-01-07
AU2013352105A1 (en) 2015-06-18
MX2015006538A (es) 2015-09-23
RS61513B1 (sr) 2021-03-31
ES2703914T3 (es) 2019-03-13
PL3495495T3 (pl) 2021-08-30
HRP20210451T1 (hr) 2021-05-14
NZ708654A (en) 2020-04-24
HRP20181991T1 (hr) 2019-03-08
HK1215874A1 (zh) 2016-09-23
CY1124140T1 (el) 2022-05-27
JP2018099127A (ja) 2018-06-28
KR20200128446A (ko) 2020-11-12
EP2925889A4 (en) 2016-06-15
IL270636B (en) 2021-04-29
AU2013352105B2 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
DK2885010T3 (da) Fremgangsmåder til behandling med tauopati
DK2872491T3 (da) Inhibitorer af fibroblastvækstfaktorreceptoren
CO7030960A2 (es) Inhibidores de pak para el tratamiento de los trastornos de proliferación celular
DK2925889T3 (da) Diagnostiske markører til behandling af celleproliferationsforstyrrelser med telomeraseinhibitorer
DK2819602T3 (da) Kateter til behandling af atrieflagren med enkelt-virkende dobbelt afbøjningsmekanisme
DK2844256T3 (da) Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
DK2701733T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
DK2818241T3 (da) Fremgangsmåde til fremstilling af behandlingsapparat udstyret med katalysatorbærende honeycombstruktur
CO6880068A2 (es) Aminoquinazolinas como inhibidores de quinasa
DK2828208T3 (da) Aktivering af persulfater med organisk syre
DK2833884T3 (da) Anvendelse af ccr3-inhibitorer
DK2903432T3 (da) Fremgangsmåde til behandling af sædceller til kønsortering
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK2914310T3 (da) Medicinske indretninger med coatings til forbedret ekkogenicitet
DK2892556T3 (da) Sammensætninger og fremgangsmåder til behandling af sygdomme
DK2705847T3 (da) Sammensætning til behandling af psoriasis
DK2825636T3 (da) Behandling af sædceller
DK3590960T3 (da) Igg-stimuleret remyelinisering af perifere nerver
DK3473276T3 (da) Teknikker til behandling af abscesser
DK2920342T3 (da) Indretning til digelfri zonesmeltning af krystalstave
FR2997080B1 (fr) Inhibiteurs de neprilysine
DK2704705T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK2811993T3 (da) Fremgangsmåder til behandling af fibrose
UA29879S (uk) Комплект монтажних пластин для лижного кріплення